A growing number of anticancer therapies once available only as intravenous (IV) infusions now have subcutaneous formulations. These can shorten chair time for patients and change how infusion centers ...
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer. To better understand the potential clinical implications of ...
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC. The TRIPL trial (NCT06865339) is testing thoracic ...
Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer. In an interview with ...
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain ...
Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...
Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with ...
The FDA has approved pirtobrutinib (Jaypirca) monotherapy as a treatment for adults with previously untreated chronic ...
Patient enrollment of the phase 3 IDeate-Lung02 trial assessing I-DXd vs chemotherapy in relapsed ES-SCLC will continue ...
In a conversation with CancerNetwork ® at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition, Jeffrey V. Matous, MD, discussed the feasibility of standardiz ...
Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than ...
Resection combined with cesium-131 collagen tile-based radiation therapy (TBRT; GammaTile) significantly improved time to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results